| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Neoplasms | 70 | 2018 | 4849 | 2.280 |
Why?
|
| Glioma | 32 | 2018 | 1963 | 1.540 |
Why?
|
| Glioblastoma | 33 | 2018 | 1797 | 1.510 |
Why?
|
| Breast Neoplasms | 61 | 2020 | 15694 | 1.390 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 56 | 2020 | 15862 | 1.360 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 21 | 2011 | 2508 | 1.040 |
Why?
|
| Receptor, ErbB-2 | 17 | 2020 | 2518 | 0.950 |
Why?
|
| Eflornithine | 4 | 2018 | 59 | 0.920 |
Why?
|
| Gene Expression Profiling | 22 | 2020 | 5159 | 0.880 |
Why?
|
| Neoplasms | 38 | 2021 | 15193 | 0.850 |
Why?
|
| Astrocytoma | 11 | 2013 | 321 | 0.850 |
Why?
|
| Survival Analysis | 50 | 2020 | 9180 | 0.830 |
Why?
|
| Proportional Hazards Models | 25 | 2017 | 4988 | 0.810 |
Why?
|
| Middle Aged | 194 | 2020 | 86204 | 0.810 |
Why?
|
| Aged | 168 | 2020 | 70117 | 0.790 |
Why?
|
| Receptors, Estrogen | 12 | 2020 | 2086 | 0.790 |
Why?
|
| Adult | 170 | 2020 | 77950 | 0.760 |
Why?
|
| Biomarkers, Tumor | 37 | 2020 | 10331 | 0.750 |
Why?
|
| Pancreatic Neoplasms | 21 | 2020 | 5061 | 0.750 |
Why?
|
| Humans | 285 | 2021 | 261506 | 0.700 |
Why?
|
| Female | 213 | 2020 | 141928 | 0.680 |
Why?
|
| Antineoplastic Agents | 28 | 2020 | 14289 | 0.630 |
Why?
|
| Neoplasm Recurrence, Local | 36 | 2018 | 10035 | 0.630 |
Why?
|
| Antibodies, Monoclonal, Humanized | 17 | 2020 | 3251 | 0.590 |
Why?
|
| Kaplan-Meier Estimate | 22 | 2020 | 6207 | 0.570 |
Why?
|
| Adenocarcinoma | 23 | 2016 | 7789 | 0.560 |
Why?
|
| Melanoma | 11 | 2019 | 5317 | 0.540 |
Why?
|
| Prognosis | 74 | 2020 | 21713 | 0.540 |
Why?
|
| Triple Negative Breast Neoplasms | 8 | 2020 | 1215 | 0.530 |
Why?
|
| Aged, 80 and over | 63 | 2020 | 29902 | 0.530 |
Why?
|
| Male | 158 | 2020 | 123000 | 0.520 |
Why?
|
| Clinical Trials as Topic | 5 | 2018 | 3719 | 0.520 |
Why?
|
| Gene Expression Regulation, Neoplastic | 22 | 2020 | 8873 | 0.510 |
Why?
|
| Clinical Trials, Phase I as Topic | 10 | 2016 | 604 | 0.510 |
Why?
|
| Paclitaxel | 9 | 2014 | 1996 | 0.500 |
Why?
|
| Image-Guided Biopsy | 4 | 2018 | 327 | 0.500 |
Why?
|
| Models, Statistical | 5 | 2016 | 1171 | 0.490 |
Why?
|
| Oligodendroglioma | 5 | 2007 | 106 | 0.480 |
Why?
|
| Carcinoma, Ductal, Breast | 6 | 2020 | 1216 | 0.470 |
Why?
|
| Cordotomy | 3 | 2019 | 46 | 0.470 |
Why?
|
| Neoplasms, Unknown Primary | 7 | 2008 | 192 | 0.470 |
Why?
|
| Albumins | 2 | 2014 | 258 | 0.460 |
Why?
|
| Research Design | 8 | 2018 | 1544 | 0.460 |
Why?
|
| Breast Diseases | 3 | 2020 | 201 | 0.450 |
Why?
|
| Disease-Free Survival | 38 | 2020 | 10001 | 0.450 |
Why?
|
| Retrospective Studies | 65 | 2020 | 37905 | 0.440 |
Why?
|
| Deoxycytidine | 5 | 2014 | 1353 | 0.430 |
Why?
|
| Young Adult | 39 | 2020 | 21445 | 0.430 |
Why?
|
| Skin Neoplasms | 6 | 2019 | 4654 | 0.420 |
Why?
|
| Treatment Outcome | 59 | 2020 | 32848 | 0.410 |
Why?
|
| Protein Kinase Inhibitors | 10 | 2019 | 4757 | 0.410 |
Why?
|
| Radiosurgery | 8 | 2019 | 1330 | 0.400 |
Why?
|
| Algorithms | 7 | 2016 | 3890 | 0.390 |
Why?
|
| Central Nervous System Neoplasms | 3 | 2020 | 502 | 0.390 |
Why?
|
| Receptors, Progesterone | 6 | 2020 | 1392 | 0.390 |
Why?
|
| Biostatistics | 1 | 2010 | 20 | 0.380 |
Why?
|
| Biopsy, Needle | 9 | 2019 | 1363 | 0.380 |
Why?
|
| Antineoplastic Agents, Immunological | 5 | 2020 | 1249 | 0.380 |
Why?
|
| Neoplasm Metastasis | 12 | 2019 | 5112 | 0.370 |
Why?
|
| Survival Rate | 39 | 2020 | 12221 | 0.370 |
Why?
|
| Ipilimumab | 4 | 2019 | 710 | 0.370 |
Why?
|
| Immunotherapy | 6 | 2018 | 3341 | 0.360 |
Why?
|
| Research | 2 | 2011 | 415 | 0.350 |
Why?
|
| Sirolimus | 8 | 2017 | 814 | 0.350 |
Why?
|
| Statistics as Topic | 1 | 2011 | 445 | 0.350 |
Why?
|
| Cancer Pain | 3 | 2019 | 312 | 0.340 |
Why?
|
| Bone Neoplasms | 6 | 2019 | 2576 | 0.340 |
Why?
|
| Mammography | 9 | 2020 | 1010 | 0.340 |
Why?
|
| Chemotherapy, Adjuvant | 17 | 2020 | 3890 | 0.330 |
Why?
|
| Magnetic Resonance Imaging | 15 | 2020 | 7702 | 0.330 |
Why?
|
| Neoplasm Staging | 24 | 2019 | 13658 | 0.330 |
Why?
|
| Disease Progression | 20 | 2020 | 6682 | 0.330 |
Why?
|
| Follow-Up Studies | 23 | 2020 | 14889 | 0.320 |
Why?
|
| Clinical Trials, Phase II as Topic | 4 | 2018 | 665 | 0.320 |
Why?
|
| Fluorouracil | 12 | 2020 | 1944 | 0.320 |
Why?
|
| Pyrimidinones | 3 | 2019 | 314 | 0.320 |
Why?
|
| Gene Expression | 8 | 2018 | 3570 | 0.310 |
Why?
|
| Angiogenesis Inhibitors | 7 | 2015 | 1248 | 0.310 |
Why?
|
| Mutation | 13 | 2020 | 15179 | 0.300 |
Why?
|
| Oximes | 2 | 2019 | 175 | 0.300 |
Why?
|
| Dacarbazine | 7 | 2014 | 485 | 0.300 |
Why?
|
| Hydroxamic Acids | 4 | 2015 | 442 | 0.290 |
Why?
|
| Lung Neoplasms | 13 | 2020 | 11538 | 0.290 |
Why?
|
| Neurosurgical Procedures | 1 | 2012 | 609 | 0.290 |
Why?
|
| Neoadjuvant Therapy | 16 | 2020 | 4975 | 0.290 |
Why?
|
| Rare Diseases | 2 | 2020 | 351 | 0.290 |
Why?
|
| Bevacizumab | 6 | 2017 | 938 | 0.280 |
Why?
|
| Pain, Intractable | 2 | 2019 | 171 | 0.280 |
Why?
|
| Liver Neoplasms | 8 | 2019 | 4557 | 0.280 |
Why?
|
| Adolescent | 42 | 2019 | 31252 | 0.280 |
Why?
|
| Sarcoma, Ewing | 3 | 2016 | 406 | 0.280 |
Why?
|
| Pharmacogenetics | 1 | 2007 | 260 | 0.270 |
Why?
|
| Metformin | 3 | 2019 | 378 | 0.270 |
Why?
|
| Procarbazine | 5 | 2002 | 69 | 0.270 |
Why?
|
| Pyridones | 2 | 2019 | 348 | 0.270 |
Why?
|
| Polymorphism, Single Nucleotide | 8 | 2015 | 4549 | 0.270 |
Why?
|
| Thalidomide | 5 | 2014 | 569 | 0.270 |
Why?
|
| Databases, Genetic | 4 | 2014 | 745 | 0.260 |
Why?
|
| Genetic Markers | 5 | 2014 | 974 | 0.260 |
Why?
|
| Antibodies, Monoclonal | 7 | 2017 | 4367 | 0.260 |
Why?
|
| Isotretinoin | 4 | 2014 | 158 | 0.260 |
Why?
|
| Small Cell Lung Carcinoma | 2 | 2020 | 406 | 0.260 |
Why?
|
| Time Factors | 26 | 2018 | 12926 | 0.250 |
Why?
|
| Ultrasonography, Mammary | 5 | 2020 | 380 | 0.250 |
Why?
|
| Software | 1 | 2011 | 1321 | 0.250 |
Why?
|
| DNA Mismatch Repair | 3 | 2011 | 268 | 0.240 |
Why?
|
| Doxorubicin | 8 | 2017 | 3005 | 0.240 |
Why?
|
| Carcinoid Tumor | 3 | 2015 | 280 | 0.240 |
Why?
|
| Predictive Value of Tests | 18 | 2016 | 4892 | 0.240 |
Why?
|
| Sulfonamides | 4 | 2015 | 1823 | 0.240 |
Why?
|
| Trastuzumab | 8 | 2018 | 696 | 0.240 |
Why?
|
| Inflammatory Breast Neoplasms | 2 | 2020 | 509 | 0.230 |
Why?
|
| Fatigue | 3 | 2021 | 1239 | 0.230 |
Why?
|
| Quinolines | 2 | 2017 | 383 | 0.230 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 2 | 2016 | 328 | 0.230 |
Why?
|
| Lymphatic Metastasis | 13 | 2019 | 4844 | 0.230 |
Why?
|
| Lomustine | 4 | 2002 | 39 | 0.230 |
Why?
|
| Multivariate Analysis | 20 | 2016 | 4298 | 0.220 |
Why?
|
| Regression Analysis | 8 | 2015 | 1546 | 0.220 |
Why?
|
| Proto-Oncogene Proteins B-raf | 3 | 2019 | 1283 | 0.220 |
Why?
|
| Cyclophosphamide | 5 | 2010 | 3001 | 0.220 |
Why?
|
| Imidazoles | 2 | 2019 | 999 | 0.220 |
Why?
|
| Vascular Endothelial Growth Factor A | 7 | 2014 | 1533 | 0.220 |
Why?
|
| Testicular Neoplasms | 2 | 2016 | 529 | 0.210 |
Why?
|
| Pyrimidines | 5 | 2015 | 3518 | 0.210 |
Why?
|
| Chromosomes, Human, Pair 19 | 2 | 2017 | 143 | 0.210 |
Why?
|
| Gene Frequency | 4 | 2019 | 1163 | 0.210 |
Why?
|
| Registries | 4 | 2017 | 2170 | 0.210 |
Why?
|
| Risk Assessment | 13 | 2018 | 6869 | 0.210 |
Why?
|
| CTLA-4 Antigen | 4 | 2018 | 657 | 0.210 |
Why?
|
| Reproducibility of Results | 12 | 2018 | 6009 | 0.200 |
Why?
|
| Matrix Metalloproteinase Inhibitors | 1 | 2001 | 57 | 0.200 |
Why?
|
| Stomach Neoplasms | 7 | 2018 | 2278 | 0.200 |
Why?
|
| Combined Modality Therapy | 18 | 2020 | 8865 | 0.200 |
Why?
|
| Vincristine | 4 | 2003 | 1511 | 0.200 |
Why?
|
| Isocitrate Dehydrogenase | 2 | 2017 | 480 | 0.200 |
Why?
|
| Chromosomes, Human, Pair 1 | 2 | 2017 | 327 | 0.200 |
Why?
|
| Vindesine | 1 | 2000 | 11 | 0.200 |
Why?
|
| Tumor Burden | 5 | 2018 | 1987 | 0.200 |
Why?
|
| Drug Resistance, Neoplasm | 7 | 2018 | 5178 | 0.190 |
Why?
|
| Somatomedins | 2 | 2011 | 75 | 0.190 |
Why?
|
| Decision Support Techniques | 2 | 2016 | 622 | 0.190 |
Why?
|
| Chemoradiotherapy | 3 | 2020 | 1946 | 0.190 |
Why?
|
| Peptide Fragments | 4 | 2012 | 1271 | 0.180 |
Why?
|
| Surgical Instruments | 2 | 2019 | 138 | 0.180 |
Why?
|
| Molecular Targeted Therapy | 4 | 2018 | 2330 | 0.180 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2018 | 1756 | 0.180 |
Why?
|
| Cognition Disorders | 2 | 2003 | 786 | 0.180 |
Why?
|
| Solitary Pulmonary Nodule | 1 | 2001 | 123 | 0.180 |
Why?
|
| Patient Selection | 6 | 2018 | 2055 | 0.180 |
Why?
|
| Melatonin | 1 | 2020 | 46 | 0.180 |
Why?
|
| Spinothalamic Tracts | 1 | 2019 | 19 | 0.180 |
Why?
|
| Ampulla of Vater | 1 | 2000 | 155 | 0.180 |
Why?
|
| Confidence Intervals | 5 | 2004 | 756 | 0.180 |
Why?
|
| RNA, Messenger | 13 | 2013 | 6150 | 0.170 |
Why?
|
| Phototherapy | 1 | 2020 | 75 | 0.170 |
Why?
|
| Antineoplastic Agents, Alkylating | 5 | 2014 | 588 | 0.170 |
Why?
|
| TOR Serine-Threonine Kinases | 5 | 2018 | 1546 | 0.170 |
Why?
|
| Cervical Cord | 1 | 2019 | 19 | 0.170 |
Why?
|
| Methylphenidate | 1 | 2020 | 103 | 0.170 |
Why?
|
| Enzyme Inhibitors | 4 | 2006 | 1879 | 0.170 |
Why?
|
| Mefloquine | 1 | 2018 | 10 | 0.170 |
Why?
|
| Biomedical Research | 3 | 2016 | 806 | 0.170 |
Why?
|
| Karnofsky Performance Status | 8 | 2008 | 175 | 0.160 |
Why?
|
| Memantine | 1 | 2018 | 46 | 0.160 |
Why?
|
| Hospitals, High-Volume | 1 | 2019 | 77 | 0.160 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2019 | 2291 | 0.160 |
Why?
|
| Watchful Waiting | 2 | 2018 | 289 | 0.160 |
Why?
|
| Interleukin-9 | 1 | 2018 | 37 | 0.160 |
Why?
|
| Spinal Cord | 4 | 2019 | 690 | 0.160 |
Why?
|
| Aortic Aneurysm, Abdominal | 4 | 2002 | 384 | 0.160 |
Why?
|
| Risk Factors | 19 | 2018 | 17523 | 0.160 |
Why?
|
| Carcinoma, Lobular | 3 | 2020 | 611 | 0.160 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2020 | 134 | 0.160 |
Why?
|
| Central Nervous System Stimulants | 1 | 2020 | 225 | 0.160 |
Why?
|
| Physical Exertion | 1 | 2018 | 113 | 0.160 |
Why?
|
| Caveolae | 1 | 2017 | 20 | 0.160 |
Why?
|
| Protein Kinases | 3 | 2015 | 874 | 0.160 |
Why?
|
| Carcinoma | 6 | 2010 | 2578 | 0.160 |
Why?
|
| Eligibility Determination | 1 | 2018 | 77 | 0.150 |
Why?
|
| Genes, BRCA2 | 1 | 2020 | 309 | 0.150 |
Why?
|
| Anticonvulsants | 5 | 2007 | 431 | 0.150 |
Why?
|
| Phthalazines | 1 | 2019 | 253 | 0.150 |
Why?
|
| Parathyroid Neoplasms | 1 | 2019 | 185 | 0.150 |
Why?
|
| Tissue Extracts | 1 | 2017 | 48 | 0.150 |
Why?
|
| Decision Making | 4 | 2019 | 1287 | 0.150 |
Why?
|
| Cicatrix | 1 | 2019 | 208 | 0.150 |
Why?
|
| Receptor, TIE-2 | 1 | 2017 | 82 | 0.150 |
Why?
|
| Prospective Studies | 17 | 2019 | 12873 | 0.150 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2019 | 224 | 0.150 |
Why?
|
| Esophageal Neoplasms | 3 | 2019 | 3168 | 0.150 |
Why?
|
| Genes, BRCA1 | 1 | 2020 | 387 | 0.150 |
Why?
|
| Immunohistochemistry | 16 | 2018 | 7548 | 0.150 |
Why?
|
| Postmenopause | 1 | 2019 | 378 | 0.150 |
Why?
|
| Actuarial Analysis | 2 | 1999 | 159 | 0.150 |
Why?
|
| Carcinoma, Ductal | 1 | 2018 | 145 | 0.150 |
Why?
|
| Computer Simulation | 2 | 2016 | 1529 | 0.150 |
Why?
|
| Phosphoric Monoester Hydrolases | 4 | 2005 | 243 | 0.150 |
Why?
|
| Sensitivity and Specificity | 7 | 2018 | 4971 | 0.140 |
Why?
|
| Radiotherapy, Adjuvant | 7 | 2018 | 2231 | 0.140 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2014 | 5539 | 0.140 |
Why?
|
| Breast | 7 | 2019 | 1344 | 0.140 |
Why?
|
| Glutathione Transferase | 1 | 1997 | 359 | 0.140 |
Why?
|
| Caveolin 1 | 1 | 2017 | 204 | 0.140 |
Why?
|
| Artifacts | 2 | 2019 | 532 | 0.140 |
Why?
|
| Cisplatin | 2 | 2020 | 2432 | 0.140 |
Why?
|
| Cyclin E | 1 | 2018 | 267 | 0.140 |
Why?
|
| American Cancer Society | 1 | 2016 | 31 | 0.140 |
Why?
|
| Choice Behavior | 1 | 2018 | 226 | 0.140 |
Why?
|
| Disease Models, Animal | 4 | 2018 | 7222 | 0.140 |
Why?
|
| Stereotaxic Techniques | 1 | 2017 | 172 | 0.140 |
Why?
|
| Foreign-Body Migration | 1 | 2017 | 117 | 0.140 |
Why?
|
| Age Factors | 8 | 2018 | 5377 | 0.140 |
Why?
|
| Magnetic Resonance Imaging, Interventional | 1 | 2017 | 96 | 0.140 |
Why?
|
| raf Kinases | 1 | 2016 | 81 | 0.140 |
Why?
|
| Lymph Nodes | 2 | 2018 | 2967 | 0.130 |
Why?
|
| Mice, Nude | 9 | 2016 | 4307 | 0.130 |
Why?
|
| Oligonucleotides | 2 | 2007 | 227 | 0.130 |
Why?
|
| Supratentorial Neoplasms | 3 | 2003 | 78 | 0.130 |
Why?
|
| Obesity | 2 | 2019 | 2884 | 0.130 |
Why?
|
| Computer Graphics | 1 | 1995 | 82 | 0.130 |
Why?
|
| United States | 7 | 2019 | 15433 | 0.130 |
Why?
|
| Drugs, Investigational | 1 | 2016 | 135 | 0.130 |
Why?
|
| Quality of Life | 5 | 2021 | 4532 | 0.130 |
Why?
|
| Stroke Volume | 3 | 2014 | 577 | 0.130 |
Why?
|
| Overweight | 1 | 2019 | 484 | 0.130 |
Why?
|
| Tumor Suppressor Proteins | 5 | 2006 | 1823 | 0.130 |
Why?
|
| Thyroid Carcinoma, Anaplastic | 1 | 2017 | 259 | 0.130 |
Why?
|
| Precision Medicine | 3 | 2018 | 1154 | 0.130 |
Why?
|
| Pregnancy Complications, Neoplastic | 2 | 1994 | 222 | 0.130 |
Why?
|
| Pyrazoles | 3 | 2018 | 1471 | 0.130 |
Why?
|
| Antineoplastic Agents, Phytogenic | 3 | 2020 | 852 | 0.120 |
Why?
|
| Telomerase | 3 | 2007 | 525 | 0.120 |
Why?
|
| Cell Cycle Proteins | 2 | 2018 | 2045 | 0.120 |
Why?
|
| Anti-Inflammatory Agents | 1 | 1998 | 461 | 0.120 |
Why?
|
| Glucose | 2 | 2011 | 1248 | 0.120 |
Why?
|
| Cohort Studies | 11 | 2020 | 9244 | 0.120 |
Why?
|
| Nuclear Proteins | 3 | 2018 | 3343 | 0.120 |
Why?
|
| Hypothyroidism | 1 | 2016 | 204 | 0.120 |
Why?
|
| Camptothecin | 3 | 2008 | 517 | 0.120 |
Why?
|
| Carcinoma, Papillary | 1 | 2018 | 584 | 0.120 |
Why?
|
| Chondrosarcoma | 1 | 2016 | 216 | 0.120 |
Why?
|
| Dose-Response Relationship, Drug | 10 | 2016 | 4938 | 0.120 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2019 | 7551 | 0.120 |
Why?
|
| Phenylurea Compounds | 1 | 2017 | 580 | 0.120 |
Why?
|
| Multimodal Imaging | 1 | 2018 | 550 | 0.120 |
Why?
|
| Ki-67 Antigen | 3 | 2012 | 666 | 0.120 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2014 | 160 | 0.120 |
Why?
|
| Bayes Theorem | 2 | 2016 | 1021 | 0.120 |
Why?
|
| Sarcoma | 3 | 2016 | 1725 | 0.120 |
Why?
|
| Recurrence | 4 | 2012 | 4758 | 0.120 |
Why?
|
| Bendamustine Hydrochloride | 1 | 2014 | 107 | 0.120 |
Why?
|
| Nitrogen Mustard Compounds | 1 | 2014 | 73 | 0.120 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2016 | 371 | 0.120 |
Why?
|
| Benzodiazepines | 1 | 2015 | 170 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2016 | 641 | 0.120 |
Why?
|
| Endogenous Retroviruses | 1 | 2013 | 41 | 0.120 |
Why?
|
| Biomarkers, Pharmacological | 2 | 2010 | 67 | 0.110 |
Why?
|
| Urogenital Neoplasms | 1 | 2014 | 108 | 0.110 |
Why?
|
| Cachexia | 1 | 2015 | 161 | 0.110 |
Why?
|
| Animals | 19 | 2018 | 59536 | 0.110 |
Why?
|
| Laser Therapy | 1 | 2017 | 411 | 0.110 |
Why?
|
| Autophagy | 3 | 2016 | 927 | 0.110 |
Why?
|
| Hyperlipidemias | 1 | 2015 | 235 | 0.110 |
Why?
|
| Mucositis | 1 | 2014 | 148 | 0.110 |
Why?
|
| Tumor Suppressor Protein p53 | 5 | 2015 | 3552 | 0.110 |
Why?
|
| Genes, erbB-2 | 2 | 2020 | 229 | 0.110 |
Why?
|
| Procollagen | 1 | 2012 | 31 | 0.110 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 2 | 2019 | 674 | 0.110 |
Why?
|
| Aortic Aneurysm | 3 | 1994 | 230 | 0.110 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2018 | 992 | 0.110 |
Why?
|
| Oncogene Proteins, Viral | 1 | 1993 | 133 | 0.110 |
Why?
|
| Cell Nucleus | 2 | 2017 | 1620 | 0.110 |
Why?
|
| Cell Line, Tumor | 14 | 2018 | 14551 | 0.110 |
Why?
|
| Antibiotics, Antineoplastic | 3 | 2005 | 726 | 0.110 |
Why?
|
| Physician-Patient Relations | 1 | 2019 | 792 | 0.110 |
Why?
|
| Cluster Analysis | 5 | 2007 | 1053 | 0.110 |
Why?
|
| Topotecan | 2 | 2008 | 239 | 0.110 |
Why?
|
| Maximum Tolerated Dose | 6 | 2018 | 1290 | 0.110 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2017 | 425 | 0.110 |
Why?
|
| Drug Approval | 1 | 2013 | 178 | 0.110 |
Why?
|
| Body Weight | 3 | 2015 | 1293 | 0.110 |
Why?
|
| Logistic Models | 11 | 2016 | 3441 | 0.110 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2001 | 1303 | 0.110 |
Why?
|
| Hyperglycemia | 1 | 2015 | 333 | 0.110 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 7 | 2008 | 3639 | 0.110 |
Why?
|
| RNA, Neoplasm | 6 | 2005 | 771 | 0.110 |
Why?
|
| Nephrectomy | 1 | 2017 | 779 | 0.110 |
Why?
|
| Biopsy | 6 | 2020 | 3443 | 0.100 |
Why?
|
| Carboplatin | 4 | 2008 | 823 | 0.100 |
Why?
|
| Neoplasm Proteins | 6 | 2002 | 3230 | 0.100 |
Why?
|
| ErbB Receptors | 5 | 2011 | 2295 | 0.100 |
Why?
|
| Probability | 4 | 2007 | 866 | 0.100 |
Why?
|
| Antimetabolites, Antineoplastic | 5 | 2020 | 1299 | 0.100 |
Why?
|
| Bile Duct Neoplasms | 2 | 2013 | 493 | 0.100 |
Why?
|
| Glutamine-Fructose-6-Phosphate Transaminase (Isomerizing) | 1 | 2011 | 3 | 0.100 |
Why?
|
| Extracellular Space | 1 | 2011 | 132 | 0.100 |
Why?
|
| Glucokinase | 1 | 2011 | 21 | 0.100 |
Why?
|
| Pneumonia | 1 | 2017 | 751 | 0.100 |
Why?
|
| Glucose-6-Phosphate Isomerase | 1 | 2011 | 24 | 0.100 |
Why?
|
| DNA, Neoplasm | 3 | 2014 | 1910 | 0.100 |
Why?
|
| Hexokinase | 1 | 2011 | 36 | 0.100 |
Why?
|
| Antihypertensive Agents | 1 | 2014 | 395 | 0.100 |
Why?
|
| N-Acetylglucosaminyltransferases | 1 | 2011 | 46 | 0.100 |
Why?
|
| In Situ Hybridization, Fluorescence | 4 | 2016 | 2232 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2014 | 419 | 0.100 |
Why?
|
| Genes, p53 | 2 | 2014 | 1090 | 0.100 |
Why?
|
| Celecoxib | 2 | 2014 | 200 | 0.100 |
Why?
|
| Neoplastic Stem Cells | 2 | 2016 | 1443 | 0.100 |
Why?
|
| Lung Diseases | 2 | 2010 | 717 | 0.100 |
Why?
|
| Neovascularization, Pathologic | 3 | 2015 | 1547 | 0.100 |
Why?
|
| RNA, Viral | 1 | 2013 | 671 | 0.100 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2015 | 612 | 0.100 |
Why?
|
| Quinazolines | 3 | 2011 | 923 | 0.100 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2013 | 334 | 0.090 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2017 | 2326 | 0.090 |
Why?
|
| Pituitary Neoplasms | 1 | 2012 | 203 | 0.090 |
Why?
|
| Polymerase Chain Reaction | 5 | 2011 | 3203 | 0.090 |
Why?
|
| Gallbladder Neoplasms | 1 | 2013 | 245 | 0.090 |
Why?
|
| DNA-Binding Proteins | 5 | 2006 | 4821 | 0.090 |
Why?
|
| Databases, Factual | 4 | 2018 | 2218 | 0.090 |
Why?
|
| Proteome | 1 | 2014 | 561 | 0.090 |
Why?
|
| ras Proteins | 1 | 2014 | 770 | 0.090 |
Why?
|
| Body Mass Index | 1 | 2018 | 2203 | 0.090 |
Why?
|
| Colonic Neoplasms | 1 | 2018 | 1390 | 0.090 |
Why?
|
| Mitotane | 2 | 1994 | 39 | 0.090 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2011 | 315 | 0.090 |
Why?
|
| Analysis of Variance | 7 | 2013 | 2307 | 0.090 |
Why?
|
| Incidence | 5 | 2018 | 5673 | 0.090 |
Why?
|
| Isoflavones | 1 | 2010 | 72 | 0.090 |
Why?
|
| Genotype | 7 | 2011 | 4109 | 0.090 |
Why?
|
| Cardiac Volume | 1 | 1989 | 18 | 0.090 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2010 | 299 | 0.090 |
Why?
|
| Verbal Learning | 1 | 2009 | 84 | 0.090 |
Why?
|
| Osteosarcoma | 1 | 2016 | 929 | 0.090 |
Why?
|
| Piperazines | 2 | 2009 | 2101 | 0.090 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2009 | 153 | 0.090 |
Why?
|
| Kidney Neoplasms | 2 | 2017 | 3022 | 0.090 |
Why?
|
| Cyclooxygenase 2 | 2 | 2009 | 483 | 0.090 |
Why?
|
| Proton Therapy | 1 | 2019 | 1577 | 0.090 |
Why?
|
| Collagen | 2 | 2002 | 752 | 0.090 |
Why?
|
| Texas | 7 | 2018 | 6311 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2018 | 2594 | 0.080 |
Why?
|
| Cranial Irradiation | 2 | 2009 | 315 | 0.080 |
Why?
|
| Data Collection | 2 | 2001 | 620 | 0.080 |
Why?
|
| Neuroendocrine Tumors | 1 | 2015 | 634 | 0.080 |
Why?
|
| Child | 14 | 2019 | 29154 | 0.080 |
Why?
|
| Homeodomain Proteins | 2 | 2005 | 1143 | 0.080 |
Why?
|
| Chemokine CXCL12 | 1 | 2009 | 132 | 0.080 |
Why?
|
| Meningeal Neoplasms | 2 | 2008 | 441 | 0.080 |
Why?
|
| Aortic Rupture | 1 | 1989 | 113 | 0.080 |
Why?
|
| Cardiac Output | 1 | 1989 | 194 | 0.080 |
Why?
|
| Meningeal Carcinomatosis | 1 | 2008 | 31 | 0.080 |
Why?
|
| Meningitis | 1 | 2009 | 112 | 0.080 |
Why?
|
| Drug Interactions | 4 | 2007 | 553 | 0.080 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2019 | 2104 | 0.080 |
Why?
|
| Coronary Disease | 2 | 1991 | 764 | 0.080 |
Why?
|
| Signal Transduction | 6 | 2017 | 11965 | 0.080 |
Why?
|
| Tissue Distribution | 2 | 2007 | 875 | 0.080 |
Why?
|
| Administration, Oral | 4 | 2019 | 1544 | 0.080 |
Why?
|
| Cytokines | 2 | 2015 | 2809 | 0.080 |
Why?
|
| Infusions, Intravenous | 6 | 2014 | 1382 | 0.080 |
Why?
|
| Blood Pressure | 1 | 2014 | 1467 | 0.080 |
Why?
|
| Apoptosis | 6 | 2018 | 7591 | 0.080 |
Why?
|
| Macaca mulatta | 2 | 2001 | 717 | 0.080 |
Why?
|
| Spermine | 1 | 2007 | 25 | 0.080 |
Why?
|
| Least-Squares Analysis | 1 | 2007 | 66 | 0.080 |
Why?
|
| Cholangiocarcinoma | 1 | 2013 | 493 | 0.080 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2020 | 5437 | 0.080 |
Why?
|
| Sequence Analysis, DNA | 1 | 2015 | 2483 | 0.080 |
Why?
|
| Models, Genetic | 1 | 2011 | 1113 | 0.080 |
Why?
|
| Polyamines | 1 | 2007 | 75 | 0.080 |
Why?
|
| p21-Activated Kinases | 1 | 2007 | 122 | 0.080 |
Why?
|
| Endpoint Determination | 2 | 2004 | 176 | 0.070 |
Why?
|
| Drug Administration Schedule | 6 | 2015 | 3472 | 0.070 |
Why?
|
| Carmustine | 2 | 2004 | 214 | 0.070 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2014 | 2488 | 0.070 |
Why?
|
| Taxoids | 2 | 2018 | 967 | 0.070 |
Why?
|
| Adrenal Cortex Neoplasms | 2 | 1994 | 223 | 0.070 |
Why?
|
| DNA | 3 | 2015 | 2693 | 0.070 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 2 | 3 | 2005 | 89 | 0.070 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 1989 | 244 | 0.070 |
Why?
|
| Thyroid Neoplasms | 1 | 2017 | 1866 | 0.070 |
Why?
|
| Antibodies, Viral | 1 | 2013 | 1320 | 0.070 |
Why?
|
| Linear Models | 2 | 2007 | 1085 | 0.070 |
Why?
|
| Area Under Curve | 5 | 2010 | 700 | 0.070 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2009 | 297 | 0.070 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 2 | 2020 | 341 | 0.070 |
Why?
|
| DNA, Complementary | 3 | 2003 | 869 | 0.070 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2011 | 607 | 0.070 |
Why?
|
| Periodicals as Topic | 1 | 2011 | 338 | 0.070 |
Why?
|
| Learning | 1 | 2010 | 403 | 0.070 |
Why?
|
| Risk | 5 | 2017 | 1972 | 0.070 |
Why?
|
| Paraplegia | 2 | 1998 | 95 | 0.070 |
Why?
|
| Eye Proteins | 2 | 2005 | 269 | 0.070 |
Why?
|
| Neoplasm Grading | 3 | 2017 | 1742 | 0.070 |
Why?
|
| Biomarkers | 5 | 2017 | 5047 | 0.070 |
Why?
|
| Memory | 1 | 2009 | 429 | 0.070 |
Why?
|
| Cell Proliferation | 4 | 2016 | 7226 | 0.070 |
Why?
|
| Genes, Overlapping | 1 | 2005 | 13 | 0.070 |
Why?
|
| Joint Diseases | 1 | 2006 | 71 | 0.070 |
Why?
|
| Age of Onset | 2 | 2005 | 827 | 0.070 |
Why?
|
| Thiazoles | 1 | 2010 | 726 | 0.070 |
Why?
|
| Everolimus | 2 | 2019 | 415 | 0.070 |
Why?
|
| Necrosis | 3 | 2020 | 580 | 0.070 |
Why?
|
| Histones | 1 | 2012 | 1466 | 0.070 |
Why?
|
| Neuropsychological Tests | 3 | 2009 | 1178 | 0.070 |
Why?
|
| Nervous System Neoplasms | 1 | 2005 | 36 | 0.070 |
Why?
|
| In Situ Hybridization | 2 | 2004 | 1037 | 0.070 |
Why?
|
| Microarray Analysis | 1 | 2006 | 392 | 0.060 |
Why?
|
| Loss of Heterozygosity | 3 | 2005 | 602 | 0.060 |
Why?
|
| Arrhythmias, Cardiac | 1 | 1989 | 473 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 5 | 2005 | 5395 | 0.060 |
Why?
|
| Complementary Therapies | 1 | 2006 | 126 | 0.060 |
Why?
|
| Receptor, trkB | 1 | 2005 | 53 | 0.060 |
Why?
|
| Liver Diseases | 1 | 2010 | 574 | 0.060 |
Why?
|
| Cognition | 2 | 2009 | 968 | 0.060 |
Why?
|
| Feasibility Studies | 4 | 2020 | 2292 | 0.060 |
Why?
|
| Genetic Variation | 2 | 2011 | 2086 | 0.060 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2008 | 600 | 0.060 |
Why?
|
| DNA Repair | 2 | 2018 | 1872 | 0.060 |
Why?
|
| Genetic Association Studies | 3 | 2017 | 1084 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2005 | 135 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-akt | 4 | 2017 | 2054 | 0.060 |
Why?
|
| Aortic Aneurysm, Thoracic | 3 | 2002 | 595 | 0.060 |
Why?
|
| Fenretinide | 1 | 2004 | 96 | 0.060 |
Why?
|
| Mice | 11 | 2018 | 34495 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2013 | 1489 | 0.060 |
Why?
|
| Drainage | 3 | 2002 | 416 | 0.060 |
Why?
|
| Soft Tissue Neoplasms | 2 | 2002 | 882 | 0.060 |
Why?
|
| Phosphorylation | 4 | 2017 | 4804 | 0.060 |
Why?
|
| Sex Factors | 3 | 2004 | 2139 | 0.060 |
Why?
|
| Deoxyguanosine | 1 | 2004 | 37 | 0.060 |
Why?
|
| Pilot Projects | 3 | 2019 | 2803 | 0.060 |
Why?
|
| Capecitabine | 2 | 2019 | 388 | 0.060 |
Why?
|
| Physical Examination | 2 | 2015 | 299 | 0.060 |
Why?
|
| Telomere | 1 | 2007 | 505 | 0.060 |
Why?
|
| Anthracyclines | 1 | 2005 | 331 | 0.060 |
Why?
|
| Immunologic Factors | 2 | 2017 | 649 | 0.060 |
Why?
|
| Alkyl and Aryl Transferases | 1 | 2004 | 87 | 0.060 |
Why?
|
| Drug Therapy, Combination | 3 | 2019 | 2315 | 0.060 |
Why?
|
| Climacteric | 1 | 2003 | 3 | 0.060 |
Why?
|
| Adenosine Triphosphatases | 1 | 2006 | 435 | 0.060 |
Why?
|
| DNA Helicases | 1 | 2006 | 434 | 0.060 |
Why?
|
| Nomograms | 1 | 2005 | 313 | 0.060 |
Why?
|
| tau Proteins | 1 | 2005 | 216 | 0.060 |
Why?
|
| Indazoles | 2 | 2015 | 297 | 0.060 |
Why?
|
| Cell Differentiation | 3 | 2016 | 4078 | 0.060 |
Why?
|
| Transforming Growth Factor beta | 1 | 2009 | 1130 | 0.060 |
Why?
|
| Societies, Medical | 2 | 2017 | 1335 | 0.060 |
Why?
|
| ROC Curve | 1 | 2006 | 1183 | 0.060 |
Why?
|
| Electrocardiography | 1 | 1989 | 1145 | 0.060 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2015 | 2027 | 0.060 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2008 | 840 | 0.060 |
Why?
|
| Double-Blind Method | 2 | 2020 | 2588 | 0.060 |
Why?
|
| Activities of Daily Living | 2 | 2003 | 552 | 0.050 |
Why?
|
| NF-kappa B | 2 | 2010 | 1549 | 0.050 |
Why?
|
| Genes, Neoplasm | 1 | 2004 | 324 | 0.050 |
Why?
|
| Diagnosis, Differential | 3 | 2020 | 4744 | 0.050 |
Why?
|
| Thymidine | 1 | 2002 | 155 | 0.050 |
Why?
|
| Statistics, Nonparametric | 3 | 2013 | 980 | 0.050 |
Why?
|
| Precancerous Conditions | 1 | 2009 | 1058 | 0.050 |
Why?
|
| Aorta, Abdominal | 3 | 1993 | 152 | 0.050 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2009 | 703 | 0.050 |
Why?
|
| Phosphoproteins | 1 | 2007 | 1152 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 4 | 2018 | 3981 | 0.050 |
Why?
|
| Radiation Injuries | 1 | 2009 | 1411 | 0.050 |
Why?
|
| Carbamates | 1 | 2002 | 77 | 0.050 |
Why?
|
| Genes, Tumor Suppressor | 3 | 2005 | 1064 | 0.050 |
Why?
|
| Aspirin | 1 | 2005 | 455 | 0.050 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2018 | 1048 | 0.050 |
Why?
|
| Mastectomy | 2 | 2018 | 1534 | 0.050 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2005 | 521 | 0.050 |
Why?
|
| beta-Cyclodextrins | 1 | 2001 | 18 | 0.050 |
Why?
|
| Up-Regulation | 3 | 2017 | 2450 | 0.050 |
Why?
|
| Muscle Neoplasms | 1 | 2002 | 109 | 0.050 |
Why?
|
| Spinal Cord Diseases | 1 | 2002 | 90 | 0.050 |
Why?
|
| PTEN Phosphohydrolase | 5 | 2008 | 986 | 0.050 |
Why?
|
| SEER Program | 1 | 2004 | 1000 | 0.050 |
Why?
|
| Exome | 2 | 2016 | 1239 | 0.050 |
Why?
|
| Melanoma, Experimental | 1 | 2003 | 368 | 0.050 |
Why?
|
| Kidney | 2 | 2001 | 2146 | 0.050 |
Why?
|
| Paresis | 2 | 1998 | 54 | 0.050 |
Why?
|
| Recombinant Proteins | 4 | 2011 | 2927 | 0.050 |
Why?
|
| Cytochrome P-450 Enzyme System | 3 | 2007 | 200 | 0.050 |
Why?
|
| Genes, Retinoblastoma | 1 | 2000 | 86 | 0.050 |
Why?
|
| Contrast Media | 3 | 2020 | 1472 | 0.050 |
Why?
|
| Intraoperative Complications | 2 | 2002 | 301 | 0.050 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2017 | 5319 | 0.050 |
Why?
|
| Pyrroles | 1 | 2004 | 576 | 0.050 |
Why?
|
| Adenoviridae | 1 | 2006 | 1459 | 0.050 |
Why?
|
| Genes, p16 | 1 | 2000 | 125 | 0.050 |
Why?
|
| Drug Monitoring | 1 | 2002 | 333 | 0.050 |
Why?
|
| Leiomyosarcoma | 1 | 2002 | 223 | 0.050 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2002 | 262 | 0.050 |
Why?
|
| Menogaril | 1 | 1999 | 1 | 0.050 |
Why?
|
| Neoplasm, Residual | 3 | 2018 | 1656 | 0.050 |
Why?
|
| Mitomycin | 1 | 2001 | 208 | 0.050 |
Why?
|
| Pancreaticoduodenectomy | 2 | 2001 | 690 | 0.050 |
Why?
|
| North America | 3 | 2006 | 314 | 0.050 |
Why?
|
| Repressor Proteins | 2 | 2005 | 1664 | 0.040 |
Why?
|
| Granuloma | 1 | 2001 | 154 | 0.040 |
Why?
|
| Chromosome Aberrations | 2 | 2017 | 1960 | 0.040 |
Why?
|
| Heart | 1 | 2006 | 1223 | 0.040 |
Why?
|
| Tissue Banks | 1 | 1999 | 55 | 0.040 |
Why?
|
| Polyethylene Glycols | 2 | 2017 | 615 | 0.040 |
Why?
|
| Blotting, Western | 4 | 2007 | 3536 | 0.040 |
Why?
|
| HeLa Cells | 2 | 2017 | 1643 | 0.040 |
Why?
|
| Interferon-beta | 1 | 1999 | 102 | 0.040 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2010 | 1724 | 0.040 |
Why?
|
| Abdominal Neoplasms | 1 | 2001 | 231 | 0.040 |
Why?
|
| Estrogens | 1 | 2003 | 751 | 0.040 |
Why?
|
| Retinoblastoma Protein | 1 | 2000 | 335 | 0.040 |
Why?
|
| Matrix Metalloproteinase 2 | 3 | 2005 | 256 | 0.040 |
Why?
|
| Leucovorin | 1 | 2020 | 332 | 0.040 |
Why?
|
| Internet | 2 | 2019 | 706 | 0.040 |
Why?
|
| Agglutinins | 1 | 1998 | 19 | 0.040 |
Why?
|
| Rectal Neoplasms | 2 | 1997 | 1202 | 0.040 |
Why?
|
| Data Interpretation, Statistical | 1 | 2001 | 482 | 0.040 |
Why?
|
| Genetic Heterogeneity | 2 | 2016 | 318 | 0.040 |
Why?
|
| Indoles | 1 | 2004 | 1009 | 0.040 |
Why?
|
| Pain Threshold | 1 | 2019 | 130 | 0.040 |
Why?
|
| Craniotomy | 2 | 1998 | 304 | 0.040 |
Why?
|
| Pyrazines | 1 | 2002 | 495 | 0.040 |
Why?
|
| Accreditation | 1 | 2019 | 126 | 0.040 |
Why?
|
| Polybrominated Biphenyls | 1 | 1998 | 6 | 0.040 |
Why?
|
| Indolizines | 1 | 2018 | 45 | 0.040 |
Why?
|
| Ischemia | 1 | 2002 | 391 | 0.040 |
Why?
|
| Information Systems | 2 | 1995 | 54 | 0.040 |
Why?
|
| Radiography, Thoracic | 1 | 2001 | 462 | 0.040 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2016 | 1678 | 0.040 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2019 | 134 | 0.040 |
Why?
|
| Pyridinium Compounds | 1 | 2018 | 63 | 0.040 |
Why?
|
| Hypercholesterolemia | 2 | 2015 | 259 | 0.040 |
Why?
|
| Case-Control Studies | 4 | 2011 | 6100 | 0.040 |
Why?
|
| Brain Damage, Chronic | 1 | 1998 | 37 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2000 | 476 | 0.040 |
Why?
|
| Pathology, Clinical | 1 | 1999 | 152 | 0.040 |
Why?
|
| Cyclic N-Oxides | 1 | 2018 | 106 | 0.040 |
Why?
|
| Odds Ratio | 3 | 2014 | 2316 | 0.040 |
Why?
|
| Androstadienes | 1 | 2019 | 165 | 0.040 |
Why?
|
| Lymphocytes | 2 | 2003 | 1234 | 0.040 |
Why?
|
| Lung | 2 | 2016 | 3151 | 0.040 |
Why?
|
| Cancer Vaccines | 1 | 2003 | 697 | 0.040 |
Why?
|
| Protective Factors | 1 | 2018 | 106 | 0.040 |
Why?
|
| Organelles | 1 | 1997 | 40 | 0.040 |
Why?
|
| Panax | 1 | 2017 | 33 | 0.040 |
Why?
|
| Gamma Rays | 1 | 1998 | 242 | 0.040 |
Why?
|
| Erlotinib Hydrochloride | 2 | 2010 | 388 | 0.040 |
Why?
|
| Subcellular Fractions | 1 | 1997 | 201 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 2 | 2011 | 1077 | 0.040 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2018 | 1763 | 0.040 |
Why?
|
| Sister Chromatid Exchange | 1 | 1997 | 45 | 0.040 |
Why?
|
| Bone and Bones | 1 | 2001 | 619 | 0.040 |
Why?
|
| BRCA2 Protein | 1 | 2019 | 358 | 0.040 |
Why?
|
| Cells, Cultured | 3 | 2011 | 5637 | 0.040 |
Why?
|
| Elafin | 1 | 2017 | 34 | 0.040 |
Why?
|
| Palliative Care | 2 | 2006 | 2037 | 0.040 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2017 | 164 | 0.040 |
Why?
|
| Alleles | 2 | 2015 | 2437 | 0.040 |
Why?
|
| Reward | 1 | 2018 | 169 | 0.040 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 1999 | 363 | 0.040 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2002 | 519 | 0.040 |
Why?
|
| Occult Blood | 1 | 1997 | 64 | 0.040 |
Why?
|
| Valine | 1 | 2017 | 176 | 0.040 |
Why?
|
| Phenotype | 3 | 2016 | 6295 | 0.040 |
Why?
|
| Carcinogens | 1 | 1998 | 384 | 0.040 |
Why?
|
| Chi-Square Distribution | 2 | 2015 | 1323 | 0.040 |
Why?
|
| Tretinoin | 1 | 1999 | 623 | 0.040 |
Why?
|
| Sleep | 1 | 2020 | 413 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2007 | 4320 | 0.040 |
Why?
|
| Dexamethasone | 1 | 2021 | 1450 | 0.040 |
Why?
|
| Child, Preschool | 6 | 2015 | 16273 | 0.040 |
Why?
|
| Breast Neoplasms, Male | 1 | 2018 | 229 | 0.040 |
Why?
|
| Pelvic Exenteration | 1 | 1997 | 108 | 0.040 |
Why?
|
| Nerve Tissue Proteins | 1 | 2004 | 1491 | 0.040 |
Why?
|
| Immunoenzyme Techniques | 2 | 2015 | 1165 | 0.040 |
Why?
|
| Affect | 1 | 2018 | 288 | 0.040 |
Why?
|
| BRCA1 Protein | 1 | 2019 | 493 | 0.040 |
Why?
|
| Single-Blind Method | 1 | 2017 | 409 | 0.030 |
Why?
|
| Informed Consent | 1 | 1999 | 419 | 0.030 |
Why?
|
| Steroids | 1 | 1998 | 356 | 0.030 |
Why?
|
| Ependymoma | 1 | 1998 | 242 | 0.030 |
Why?
|
| Induction Chemotherapy | 1 | 2019 | 669 | 0.030 |
Why?
|
| Medulloblastoma | 1 | 2001 | 540 | 0.030 |
Why?
|
| Radiography | 3 | 1999 | 1904 | 0.030 |
Why?
|
| Flow Cytometry | 2 | 2016 | 3033 | 0.030 |
Why?
|
| Environmental Exposure | 1 | 1998 | 288 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2002 | 2283 | 0.030 |
Why?
|
| Estrogen Receptor alpha | 1 | 2020 | 701 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2017 | 644 | 0.030 |
Why?
|
| Colorectal Neoplasms | 2 | 2004 | 3578 | 0.030 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2016 | 289 | 0.030 |
Why?
|
| Retreatment | 1 | 2016 | 452 | 0.030 |
Why?
|
| Medical History Taking | 1 | 1996 | 173 | 0.030 |
Why?
|
| Isoenzymes | 1 | 1997 | 614 | 0.030 |
Why?
|
| Protein Transport | 1 | 2017 | 734 | 0.030 |
Why?
|
| Radiation Tolerance | 1 | 1998 | 629 | 0.030 |
Why?
|
| Metastasectomy | 1 | 2017 | 200 | 0.030 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2019 | 479 | 0.030 |
Why?
|
| Stress, Physiological | 1 | 2018 | 492 | 0.030 |
Why?
|
| Motivation | 1 | 2018 | 499 | 0.030 |
Why?
|
| Chromosome Mapping | 1 | 1998 | 1471 | 0.030 |
Why?
|
| Pyridines | 1 | 2002 | 1244 | 0.030 |
Why?
|
| Ghrelin | 1 | 2015 | 79 | 0.030 |
Why?
|
| Receptors, Cell Surface | 1 | 1998 | 862 | 0.030 |
Why?
|
| Bias | 1 | 1995 | 205 | 0.030 |
Why?
|
| Reproductive History | 1 | 1994 | 25 | 0.030 |
Why?
|
| Medication Adherence | 1 | 2019 | 492 | 0.030 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2017 | 303 | 0.030 |
Why?
|
| PAX6 Transcription Factor | 2 | 2005 | 53 | 0.030 |
Why?
|
| Neoplasm Transplantation | 2 | 2011 | 1519 | 0.030 |
Why?
|
| Incidental Findings | 1 | 2016 | 272 | 0.030 |
Why?
|
| Hypoglycemic Agents | 1 | 2019 | 586 | 0.030 |
Why?
|
| Genome, Human | 2 | 2015 | 1869 | 0.030 |
Why?
|
| DNA Replication | 1 | 2018 | 744 | 0.030 |
Why?
|
| Ovarian Neoplasms | 3 | 2002 | 4638 | 0.030 |
Why?
|
| Germ-Line Mutation | 1 | 2019 | 1046 | 0.030 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2017 | 544 | 0.030 |
Why?
|
| Exercise | 1 | 2021 | 1183 | 0.030 |
Why?
|
| Imatinib Mesylate | 2 | 2009 | 1665 | 0.030 |
Why?
|
| Protein Stability | 1 | 2015 | 370 | 0.030 |
Why?
|
| Paired Box Transcription Factors | 2 | 2005 | 134 | 0.030 |
Why?
|
| Epidemiologic Methods | 1 | 1994 | 254 | 0.030 |
Why?
|
| Methods | 1 | 1993 | 189 | 0.030 |
Why?
|
| Injections, Spinal | 2 | 2008 | 257 | 0.030 |
Why?
|
| Sex Distribution | 2 | 2006 | 495 | 0.030 |
Why?
|
| Cancer Care Facilities | 1 | 2018 | 884 | 0.030 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2015 | 347 | 0.030 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 1996 | 749 | 0.030 |
Why?
|
| Leptin | 1 | 2015 | 295 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2017 | 1489 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2016 | 1391 | 0.030 |
Why?
|
| Postoperative Complications | 3 | 2000 | 5542 | 0.030 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2015 | 355 | 0.030 |
Why?
|
| Age Distribution | 2 | 2006 | 698 | 0.030 |
Why?
|
| Duodenal Neoplasms | 1 | 1994 | 138 | 0.030 |
Why?
|
| Proteolysis | 1 | 2015 | 370 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2016 | 524 | 0.030 |
Why?
|
| Preoperative Care | 4 | 2005 | 1529 | 0.030 |
Why?
|
| Endostatins | 2 | 2002 | 48 | 0.030 |
Why?
|
| Benzamides | 2 | 2009 | 1832 | 0.030 |
Why?
|
| Osteocalcin | 1 | 2012 | 87 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 1999 | 1493 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2014 | 621 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2016 | 1313 | 0.030 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2014 | 521 | 0.030 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2018 | 923 | 0.030 |
Why?
|
| Axilla | 1 | 2015 | 902 | 0.030 |
Why?
|
| Puerto Rico | 1 | 2012 | 65 | 0.030 |
Why?
|
| Niacinamide | 1 | 2014 | 421 | 0.030 |
Why?
|
| In Situ Nick-End Labeling | 2 | 2003 | 448 | 0.030 |
Why?
|
| United States Food and Drug Administration | 1 | 2013 | 332 | 0.030 |
Why?
|
| Arteriovenous Fistula | 1 | 2013 | 92 | 0.030 |
Why?
|
| Matrix Metalloproteinase 9 | 2 | 2005 | 360 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factors | 2 | 2002 | 212 | 0.030 |
Why?
|
| Cell Survival | 2 | 2009 | 3045 | 0.030 |
Why?
|
| Collagen Type I | 1 | 2012 | 204 | 0.030 |
Why?
|
| Down-Regulation | 2 | 2009 | 2074 | 0.030 |
Why?
|
| Radiotherapy Dosage | 1 | 2019 | 3842 | 0.030 |
Why?
|
| Endothelial Growth Factors | 2 | 2002 | 197 | 0.030 |
Why?
|
| Fibroblast Growth Factor 2 | 2 | 2002 | 223 | 0.030 |
Why?
|
| Weight Gain | 1 | 2015 | 464 | 0.030 |
Why?
|
| Lymphokines | 2 | 2002 | 272 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2017 | 1945 | 0.020 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 1 | 2011 | 69 | 0.020 |
Why?
|
| RNA, Small Interfering | 2 | 2007 | 2216 | 0.020 |
Why?
|
| Gene Amplification | 1 | 2014 | 731 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2016 | 1033 | 0.020 |
Why?
|
| Cancer Survivors | 1 | 2018 | 650 | 0.020 |
Why?
|
| Interleukin-8 | 2 | 2005 | 519 | 0.020 |
Why?
|
| Schools, Medical | 1 | 2012 | 132 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 1209 | 0.020 |
Why?
|
| Weight Loss | 1 | 2015 | 627 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 2 | 2005 | 2314 | 0.020 |
Why?
|
| Matched-Pair Analysis | 1 | 2010 | 103 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2015 | 1038 | 0.020 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2010 | 60 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2016 | 1085 | 0.020 |
Why?
|
| Mitochondria | 2 | 2007 | 1282 | 0.020 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2013 | 340 | 0.020 |
Why?
|
| Organoplatinum Compounds | 1 | 2013 | 702 | 0.020 |
Why?
|
| Receptors, Somatomedin | 1 | 2010 | 70 | 0.020 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2010 | 132 | 0.020 |
Why?
|
| Medical Oncology | 1 | 2018 | 1423 | 0.020 |
Why?
|
| Cerebrospinal Fluid | 2 | 2002 | 120 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2018 | 3821 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2016 | 1516 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 1217 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2011 | 760 | 0.020 |
Why?
|
| Neoplasms, Second Primary | 1 | 2018 | 1350 | 0.020 |
Why?
|
| DNA Primers | 2 | 2002 | 1399 | 0.020 |
Why?
|
| Angiocardiography | 1 | 1989 | 15 | 0.020 |
Why?
|
| Models, Biological | 1 | 2018 | 3254 | 0.020 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 1991 | 314 | 0.020 |
Why?
|
| Sample Size | 1 | 2010 | 202 | 0.020 |
Why?
|
| Neutralization Tests | 1 | 2009 | 299 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2019 | 4314 | 0.020 |
Why?
|
| Oxaloacetates | 1 | 2008 | 7 | 0.020 |
Why?
|
| Uncertainty | 1 | 2011 | 320 | 0.020 |
Why?
|
| Quality Control | 1 | 2010 | 457 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2016 | 1586 | 0.020 |
Why?
|
| Diabetes Complications | 1 | 2011 | 305 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2018 | 5710 | 0.020 |
Why?
|
| Mass Screening | 1 | 1997 | 1509 | 0.020 |
Why?
|
| Transcriptome | 1 | 2017 | 1859 | 0.020 |
Why?
|
| Hodgkin Disease | 1 | 1997 | 1429 | 0.020 |
Why?
|
| Organ Specificity | 1 | 2009 | 699 | 0.020 |
Why?
|
| Guidelines as Topic | 1 | 2010 | 383 | 0.020 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2009 | 200 | 0.020 |
Why?
|
| Forecasting | 2 | 2002 | 694 | 0.020 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2014 | 1331 | 0.020 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2009 | 566 | 0.020 |
Why?
|
| Haplotypes | 1 | 2010 | 856 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 2007 | 231 | 0.020 |
Why?
|
| Interleukin-18 | 1 | 2008 | 100 | 0.020 |
Why?
|
| Cytochromes c | 1 | 2007 | 118 | 0.020 |
Why?
|
| Octreotide | 1 | 2008 | 118 | 0.020 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2007 | 83 | 0.020 |
Why?
|
| Lymph Node Excision | 1 | 2015 | 1959 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2017 | 2403 | 0.020 |
Why?
|
| Cell Cycle | 2 | 2006 | 2084 | 0.020 |
Why?
|
| RNA Interference | 1 | 2011 | 1408 | 0.020 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2007 | 133 | 0.020 |
Why?
|
| Salvage Therapy | 2 | 2009 | 2054 | 0.020 |
Why?
|
| Endocardium | 1 | 2006 | 50 | 0.020 |
Why?
|
| Anticarcinogenic Agents | 1 | 2009 | 362 | 0.020 |
Why?
|
| Hydrogen Peroxide | 1 | 2007 | 217 | 0.020 |
Why?
|
| Peptides | 1 | 2012 | 1479 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2019 | 5687 | 0.020 |
Why?
|
| Liver | 1 | 2016 | 2961 | 0.020 |
Why?
|
| Dasatinib | 1 | 2010 | 862 | 0.020 |
Why?
|
| Fibroblast Growth Factors | 1 | 2008 | 257 | 0.020 |
Why?
|
| Joints | 1 | 2006 | 47 | 0.020 |
Why?
|
| Prevalence | 1 | 2014 | 3260 | 0.020 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2008 | 342 | 0.020 |
Why?
|
| Ligands | 1 | 2009 | 995 | 0.020 |
Why?
|
| Injections, Intralesional | 1 | 2006 | 164 | 0.020 |
Why?
|
| Membrane Potentials | 1 | 2007 | 424 | 0.020 |
Why?
|
| Decision Making, Computer-Assisted | 1 | 2005 | 32 | 0.020 |
Why?
|
| Neoplasms, Ductal, Lobular, and Medullary | 1 | 2005 | 4 | 0.020 |
Why?
|
| France | 1 | 2005 | 108 | 0.020 |
Why?
|
| Microscopy, Electron | 1 | 2006 | 600 | 0.020 |
Why?
|
| RecQ Helicases | 1 | 2006 | 102 | 0.020 |
Why?
|
| Cytoplasm | 1 | 2007 | 652 | 0.020 |
Why?
|
| DNA Probes | 1 | 2005 | 217 | 0.020 |
Why?
|
| Leukemia | 1 | 1994 | 1635 | 0.020 |
Why?
|
| ets-Domain Protein Elk-1 | 1 | 2005 | 19 | 0.020 |
Why?
|
| Computational Biology | 2 | 2002 | 1271 | 0.020 |
Why?
|
| Epirubicin | 1 | 2005 | 157 | 0.020 |
Why?
|
| Ribosomal Proteins | 1 | 2005 | 118 | 0.020 |
Why?
|
| Cell Death | 1 | 2007 | 671 | 0.020 |
Why?
|
| Synucleins | 1 | 2004 | 13 | 0.020 |
Why?
|
| Propionates | 1 | 2004 | 71 | 0.020 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2005 | 191 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2009 | 677 | 0.020 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2005 | 215 | 0.020 |
Why?
|
| Enzyme Induction | 1 | 2004 | 249 | 0.020 |
Why?
|
| Neuroblastoma | 1 | 2010 | 686 | 0.020 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2007 | 361 | 0.020 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2006 | 203 | 0.020 |
Why?
|
| Protein Array Analysis | 1 | 2007 | 501 | 0.020 |
Why?
|
| Thrombocytopenia | 2 | 2002 | 846 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 2007 | 1618 | 0.010 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2007 | 534 | 0.010 |
Why?
|
| Microtubules | 1 | 2005 | 270 | 0.010 |
Why?
|
| Transcription Factor AP-1 | 1 | 2005 | 246 | 0.010 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2006 | 430 | 0.010 |
Why?
|
| Hemocyanins | 1 | 2003 | 50 | 0.010 |
Why?
|
| Heart Ventricles | 1 | 1989 | 846 | 0.010 |
Why?
|
| Pregnancy | 2 | 1994 | 7573 | 0.010 |
Why?
|
| Astrocytes | 1 | 2007 | 368 | 0.010 |
Why?
|
| Interferon-alpha | 1 | 2008 | 889 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2016 | 3869 | 0.010 |
Why?
|
| Gastrectomy | 1 | 2006 | 451 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 2004 | 682 | 0.010 |
Why?
|
| Pacemaker, Artificial | 1 | 1986 | 213 | 0.010 |
Why?
|
| Mice, Inbred C3H | 1 | 2003 | 385 | 0.010 |
Why?
|
| Lymphopenia | 1 | 2005 | 199 | 0.010 |
Why?
|
| Collagen Type XVIII | 1 | 2002 | 17 | 0.010 |
Why?
|
| Reoperation | 2 | 1999 | 1382 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 2004 | 573 | 0.010 |
Why?
|
| Length of Stay | 2 | 2001 | 1900 | 0.010 |
Why?
|
| DNA Fragmentation | 1 | 2003 | 198 | 0.010 |
Why?
|
| Ultrasonography | 1 | 1989 | 1863 | 0.010 |
Why?
|
| E-Selectin | 1 | 2002 | 103 | 0.010 |
Why?
|
| Constriction | 1 | 2002 | 55 | 0.010 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2002 | 121 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2005 | 639 | 0.010 |
Why?
|
| Endothelium | 1 | 2002 | 158 | 0.010 |
Why?
|
| Lasers | 1 | 2002 | 198 | 0.010 |
Why?
|
| Immunoglobulins | 1 | 2002 | 266 | 0.010 |
Why?
|
| Indians, North American | 1 | 2002 | 87 | 0.010 |
Why?
|
| CD3 Complex | 1 | 2002 | 314 | 0.010 |
Why?
|
| 2-Hydroxypropyl-beta-cyclodextrin | 1 | 2001 | 4 | 0.010 |
Why?
|
| Cyclodextrins | 1 | 2001 | 7 | 0.010 |
Why?
|
| Rats | 1 | 2010 | 6086 | 0.010 |
Why?
|
| Tomography, Emission-Computed | 1 | 2002 | 310 | 0.010 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2003 | 675 | 0.010 |
Why?
|
| Therapeutic Equivalency | 1 | 2001 | 49 | 0.010 |
Why?
|
| Spleen | 1 | 2003 | 676 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2005 | 1764 | 0.010 |
Why?
|
| Regional Blood Flow | 1 | 2002 | 276 | 0.010 |
Why?
|
| Hematologic Diseases | 1 | 2002 | 242 | 0.010 |
Why?
|
| Veins | 1 | 2002 | 157 | 0.010 |
Why?
|
| Life Tables | 1 | 2000 | 120 | 0.010 |
Why?
|
| Perfusion | 1 | 2002 | 293 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2011 | 1362 | 0.010 |
Why?
|
| STAT3 Transcription Factor | 1 | 2007 | 1121 | 0.010 |
Why?
|
| Random Allocation | 1 | 2002 | 703 | 0.010 |
Why?
|
| Bone Marrow Neoplasms | 1 | 2001 | 132 | 0.010 |
Why?
|
| Dogs | 1 | 2002 | 1155 | 0.010 |
Why?
|
| Ifosfamide | 1 | 2000 | 344 | 0.010 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2003 | 690 | 0.010 |
Why?
|
| Transfection | 1 | 2005 | 2944 | 0.010 |
Why?
|
| Anemia | 1 | 2005 | 689 | 0.010 |
Why?
|
| Bromodeoxyuridine | 1 | 1999 | 139 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 2001 | 460 | 0.010 |
Why?
|
| Clavicle | 1 | 1999 | 65 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2006 | 1682 | 0.010 |
Why?
|
| Morbidity | 1 | 2000 | 397 | 0.010 |
Why?
|
| Humerus | 1 | 1999 | 53 | 0.010 |
Why?
|
| Biometry | 1 | 2001 | 241 | 0.010 |
Why?
|
| Base Sequence | 1 | 2005 | 4917 | 0.010 |
Why?
|
| Multiple Myeloma | 1 | 2010 | 2138 | 0.010 |
Why?
|
| Papaverine | 1 | 1998 | 5 | 0.010 |
Why?
|
| Genes, bcl-2 | 1 | 1999 | 166 | 0.010 |
Why?
|
| Michigan | 1 | 1998 | 67 | 0.010 |
Why?
|
| Catheter Ablation | 1 | 2004 | 620 | 0.010 |
Why?
|
| Coloring Agents | 1 | 1999 | 234 | 0.010 |
Why?
|
| Cadherins | 1 | 2002 | 660 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2005 | 6089 | 0.010 |
Why?
|
| Antigens, Nuclear | 1 | 1998 | 119 | 0.010 |
Why?
|
| RNA | 1 | 2003 | 1013 | 0.010 |
Why?
|
| Epilepsy | 1 | 2006 | 883 | 0.010 |
Why?
|
| Digestive System Neoplasms | 1 | 1998 | 82 | 0.010 |
Why?
|
| Muscle Contraction | 1 | 1998 | 218 | 0.010 |
Why?
|
| Hepatectomy | 1 | 2004 | 1011 | 0.010 |
Why?
|
| Esophagectomy | 1 | 2002 | 911 | 0.010 |
Why?
|
| Mitolactol | 1 | 1997 | 5 | 0.010 |
Why?
|
| Gadolinium DTPA | 1 | 1998 | 172 | 0.010 |
Why?
|
| Spinal Cord Neoplasms | 1 | 1998 | 142 | 0.010 |
Why?
|
| Organ Size | 1 | 1999 | 690 | 0.010 |
Why?
|
| Skull | 1 | 1999 | 231 | 0.010 |
Why?
|
| Thioguanine | 1 | 1997 | 68 | 0.010 |
Why?
|
| Ploidies | 1 | 1997 | 248 | 0.010 |
Why?
|
| Vasodilator Agents | 1 | 1998 | 219 | 0.010 |
Why?
|
| Reference Values | 1 | 1999 | 1099 | 0.010 |
Why?
|
| Hypothermia, Induced | 1 | 1998 | 170 | 0.010 |
Why?
|
| DNA Topoisomerases, Type I | 1 | 1996 | 57 | 0.010 |
Why?
|
| Topoisomerase II Inhibitors | 1 | 1996 | 58 | 0.010 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2002 | 1226 | 0.010 |
Why?
|
| Hypotension | 1 | 1998 | 210 | 0.010 |
Why?
|
| Topoisomerase I Inhibitors | 1 | 1996 | 75 | 0.010 |
Why?
|
| DNA Topoisomerases, Type II | 1 | 1996 | 116 | 0.010 |
Why?
|
| Neuroprotective Agents | 1 | 1998 | 215 | 0.010 |
Why?
|
| Hydroxyurea | 1 | 1997 | 204 | 0.010 |
Why?
|
| Calcium-Binding Proteins | 1 | 1998 | 545 | 0.010 |
Why?
|
| Headache | 1 | 1996 | 163 | 0.010 |
Why?
|
| Cardiopulmonary Bypass | 1 | 1998 | 422 | 0.010 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2006 | 1833 | 0.010 |
Why?
|
| Hemangiopericytoma | 1 | 1995 | 56 | 0.010 |
Why?
|
| Vomiting | 1 | 1996 | 354 | 0.010 |
Why?
|
| Population Surveillance | 1 | 1998 | 627 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2005 | 2819 | 0.010 |
Why?
|
| Nausea | 1 | 1996 | 525 | 0.010 |
Why?
|
| Carcinoma, Small Cell | 1 | 1997 | 408 | 0.010 |
Why?
|
| Costs and Cost Analysis | 1 | 1995 | 306 | 0.010 |
Why?
|
| Diagnostic Tests, Routine | 1 | 1995 | 173 | 0.010 |
Why?
|
| Disease | 1 | 1995 | 165 | 0.010 |
Why?
|
| Vascular Patency | 1 | 1994 | 218 | 0.010 |
Why?
|
| Alcohol Drinking | 1 | 1997 | 551 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 1 | 1996 | 709 | 0.010 |
Why?
|
| Skin Diseases | 1 | 1996 | 349 | 0.010 |
Why?
|
| Patient Compliance | 1 | 1997 | 667 | 0.010 |
Why?
|
| Arteries | 1 | 1994 | 274 | 0.010 |
Why?
|
| Diarrhea | 1 | 1996 | 686 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2003 | 6942 | 0.010 |
Why?
|
| Heart Failure | 1 | 2006 | 2516 | 0.010 |
Why?
|
| Neutropenia | 1 | 1996 | 968 | 0.010 |
Why?
|
| Meningioma | 1 | 1995 | 289 | 0.010 |
Why?
|
| Angina, Unstable | 1 | 1991 | 70 | 0.010 |
Why?
|
| Infant | 2 | 1998 | 13310 | 0.010 |
Why?
|
| Angina Pectoris | 1 | 1991 | 80 | 0.010 |
Why?
|
| Remission Induction | 1 | 1997 | 3569 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2005 | 5270 | 0.010 |
Why?
|
| Lymphoma | 1 | 1998 | 1467 | 0.010 |
Why?
|
| DNA Damage | 1 | 1997 | 1954 | 0.010 |
Why?
|
| Coronary Angiography | 1 | 1991 | 598 | 0.010 |
Why?
|
| Smoking | 1 | 1997 | 2440 | 0.000 |
Why?
|
| Coronary Artery Bypass | 1 | 1991 | 708 | 0.000 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 1986 | 94 | 0.000 |
Why?
|
| Equipment Failure | 1 | 1986 | 191 | 0.000 |
Why?
|
| Aorta, Thoracic | 1 | 1986 | 546 | 0.000 |
Why?
|
| Kidney Diseases | 1 | 1986 | 691 | 0.000 |
Why?
|